Article Detail

Home > Article Detail
  • P-ISSN 1010-0695
  • E-ISSN 2288-3339

Long-term Survival of a Hepatocellular Carcinoma Patient Treated by Korean Medicine Combined with Western Therapy: a Case Report

Journal of Korean Medicine / Journal of Korean Medicine, (P)1010-0695; (E)2288-3339
2013, v.34 no.4, pp.56-62
https://doi.org/10.13048/jkm.13027




  • Downloaded
  • Viewed

Abstract

Objectives: Hepatocellular carcinoma patients have a poor prognosis and survival beyond 5 years is very rare in spite of western treatment. We report a case of long-term survival of a hepatocellular carcinoma patient treated by Korean medicine combined with western therapy. Methods: The treatment was provided from November 2004 to July 2012. Herbal medicine, acupuncture and moxibustion treatment were used as main treatment methods. We prescribed herbal medicines three times a day and performed acupuncture and moxibustion an average of 2-3 times a week. Clinical laboratory tests were performed each month and a CT scan was carried out 13 times during the treatment period. In order to evaluate the disease status, we checked the patient's abdominal circumference, weight change and subjective symptoms regularly. Results: During treatment, subjective symptoms of the patient and state of ascites due to hepatocellular carcinoma were relatively stable. The progress of hepatocellular carcinoma was gradual without worsening rapidly. Since the initial diagnosis with hepatocellular carcinoma, the patient survived for a further 7 years and 9 months treated by Korean medicine combined with western treatment. Conclusions: According to the above results, this case indicates that Korean medical treatment combined with western therapy for hepatocellular carcinoma patients has synergistic effects of prolonged survival, relief of symptoms and management of complications

keywords
Hepatocellular carcinoma, Korean medicine, long-term survival


Reference

1

1. EL-Serag HB. Hepatocellular carcinoma: anepidemiologic view. J Clin Gastroenterol.2002;35:S72-S78.

2

2. Parkin DM, Pisani P, Ferlay J. Estimates ofthe worldwide incidence of 25 major cancersin 1990. Int J Cancer. 1999;80:827-841.

3

3. Jordi B, Morris S. Management of Hepatocellularcarcinoma. Hepatology. 2005;42:1208-1236.

4

4. Fan ST, Lo CM, Liu CL, Lam CM, YuenWK, Yeung C, et al. Hepatectomy forhepatocellular carcinoma: Toward zero hospitaldeaths. Ann Surg. 1999;229:322-30.

5

5. Nagasue N, Uchida M, Makino Y, TakemotoY, Yamanoi A, Hayashi T, et al. Incidence andfactors associated with intrahepatic recurrencefollowing resection of hepatocellularcarcinoma.Gastroenterology. 1993;105:488-494.

6

6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P,Gane E, Blanc JF, et al. Sorafenib in advancedhepatocellular carcinoma. N Engl J Med.2008;359:378-390.

7

7. Yeung YP, Lo CM, Liu CL, Wong BC, FanST, Wong J. Natural history of untreatednonsurgical hepatocellular carcinoma. Am JGastroenterol. 2005;100(9):1995-2004.

8

8. Pawarode A, Voravud N, Striuranpong V,Kullavanijaya P, Patt YZ. Natural history ofuntreated primary hepatocellular carcinoma: aretrospective study of 157 patients. Am J ClinOncol. 1998; 21:386-391.

9

9. Makuuchi M, Kokudo N. Clinical practiceguidelines for hepatocellular carcinoma: thefirst evidence based guidelines in Japan. WorldJ Gastroenterol. 2006;12(5):828-829.

10

10. Park HY, Cho JH, Son CG, Cho CK. AdenoidCystic Carcinoma of the submandible in a56-year-old woman. J Korean Orient Int Med.2005:26(4):941-945.

11

11. Kim KS. Yoo HS. Jung TY. Lee YW. ChoCK. Case series of advanced or metastaticgallbladder cancer patients treated withHangAm-Dan. J Korean Orient Int Med.2010:31(3):667-74.

12

12. Yoo HS, Kim SH, Lee YW, Cho CK, LeeKH. Two Cases of Endometrial Cancer Treatedwith Palliative Herbal Medication Hangam-dan(HAD). J Korean Oriental Med. 2007:8(4):176-180.

13

13. Garrison RN, Kaelin LD, Galloway RH,Heuser LS. Malignant ascites. Clinical andexperimental observations. Ann Surg. 1986;203:644-651.

14

14. Kim SW, Lee SH, Roh BJ, Kim JC, Park SS,Lee DH. Prognostic factors affecting survivalrate in patients with hepatocellular carcinomatreated by transcatheter arterial chemoembolization.CMH. 2000;6(3):311-320.

상단으로 이동

Journal of Korean Medicine